Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lianhua Qingwen for COVID-19 symptom relief and immune regulation
ChiCTR2200065718Phase 4Not yet recruiting
- Sponsor
- Hebei Yiling Hospital
- Start
- Nov 2022
- Countries
- 1
01
Overview
Phase 4, open-label trial of Lianhua Qingwen in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hebei Yiling Hospital. Primary endpoint: Median time for main symptoms to achieve continuous remission. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
Lianhua Qingwen
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200065718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065718.